Lucinda Buescher, MD

Dermatologist
Dermatology
Accepting new patients
Call for an appointment
or

    About me

    Academic Interests:  Dermatoimmunology; Melanoma; How environment, nutrition and lifestyle impact skin health.

    Clinical Interests:  Inflammatory skin diseases including acne and psoriasis; Skin manifestations of connective tissue disease and internal malignancy; Skin cancer.

    Gender

    Female

    Education & training

    Positions
    Professor
    Department of Internal Medicine
    Division Chief, Dermatology
    Board Certifications
    Dermatology
    Medical School
    University of Missouri, Columbia, MO - 1986
    Undergraduate Degree
    University of Missouri, Columbia, MO - 1982
    Residency
    University of Missouri Hospital & Clinics, Columbia, MO - Dermatology - 1990

    Specialties

    Clinical locations

    Place

    SIU Dermatology Clinic

    751 N. Rutledge St. Suite 2300 Springfield, IL 62702
    Mon - Fri: 8:00 am-4:30 pm
    Place

    SIU Pulmonology in Decatur

    102 W. Kenwood Ave. Lower Level Decatur, IL 62526
    Mon - Fri: 8:00 am-4:30 pm

    Hospital privileges

    • Decatur Memorial Hospital, Decatur, IL
    • HSHS St. John's Hospital, Springfield, IL
    • Memorial Health, Springfield IL

    Research

    Research Interests
    Psoriasis, acne

    Clinical trials

    Trial
    Dermatology

    Corrona Psoriasis (PSO) Registry

    Active recruiting

    The objective of the Corrona Psoriasis Registry is to create a national database of patients with psoriasis. Data collected will be used to study the  disease and to evaluate the effectiveness and safety of medications approved for the treatment of psoriasis.

    Trial
    Dermatology

    A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA

    Active not recruiting

    The purpose of this study is to evaluate the long-term safety, tolerability, and effectiveness of PF-06651600(Ritlecitinib) in adult and adolescent (12 years and older) participants with Alopecia Areata.